This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Genzyme Demonstrates Depth Of MS Pipeline At AAN With Results From Multiple Sclerosis Phase Lll Trials

Stocks in this article: SAN SNY

Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that 12 data presentations, including six platform presentations, from the company’s multiple sclerosis (MS) clinical trial programs for alemtuzumab and teriflunomide will be featured at the American Academy of Neurology's (AAN) 64 th Annual Meeting in New Orleans, La., April 21-28. Presentations will include full data results from CARE-MS II (The Comparison of alemtuzumab and Rebif ® Efficacy in Multiple Sclerosis), a Phase III trial investigating alemtuzumab in MS patients who had relapsed while receiving prior MS therapy, as well as new findings from the teriflunomide clinical program, one of the largest and broadest of any MS therapy in development.

“Genzyme’s robust development programs for alemtuzumab and teriflunomide were designed to understand how these therapies can best address significant unmet medical needs of people living with MS,” said David Meeker, M.D., President and CEO, Genzyme. “We are committed to becoming a long-term partner to the MS community with the goal of raising the expectation of what life with MS can be.”

Marketing applications for teriflunomide for the treatment of relapsing forms of MS are under review by the U.S. Food & Drug Administration (FDA) and European Medicines Agency (EMA). Genzyme is on track to submit applications to the FDA and EMA for approval of alemtuzumab to treat relapsing forms of MS in the second quarter of this year.

Following are selected scientific abstracts highlighting new results from the Phase III CARE-MS II and CARE-MS I trials for alemtuzumab, as well as the Phase III TEMSO (Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis) trial for teriflunomide.

ALEMTUZUMAB CARE-MS II Platform Presentation:

  • Efficacy and Safety Results From Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis II (CARE−MS II): A Phase III Study in Relapsing−Remitting Multiple Sclerosis Patients Who Relapsed on Prior Therapy (Platform Presentation S01.004; April 24; 1:45 p.m. CT, 2:45 p.m. ET)

ALEMTUZUMAB CARE-MS I Platform Presentations:

  • Efficacy and Safety Results From Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis I (CARE−MS I): A Phase III Study in Relapsing−Remitting Treatment−Naïve Patients (Platform Presentation S01.006; April 24; 2:15 p.m. CT, 3:15 p.m. ET)
  • Effect of Alemtuzumab vs. Rebif on Brain MRI Measurements: Results of CARE−MS I, a Phase III Study (Platform Presentation S11.006; April 24; 4:15 p.m. CT, 5:15 p.m. ET)
  • Incidence of Autoimmunity in a Phase III Trial: Comparison of Alemtuzumab and Rebif in Multiple Sclerosis I (CARE−MS I) (Platform Presentation S41.006; April 26; 2:15 p.m. CT, 3:15 p.m. ET)
  • Infections in Phase III Study: Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis I (CARE−MS I) (Platform Presentation S41.007; April 26; 2:30 p.m. CT, 3:30 p.m. ET)

TERIFLUNOMIDE TEMSO Platform Presentation:

  • Effect of Teriflunomide on Relapses With Sequelae and Relapse Leading to Hospitalization in a Population With Relapsing Forms of Multiple Sclerosis: Results From the TEMSO Study (Platform Presentation S30.003; April 25; 2:30 p.m. CT, 3:30 p.m. ET)

Additional Genzyme MS portfolio data to be presented include:

1 of 5

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs